Our standard control oligo is a negative control Morpholino oligo that targets a human beta-globin intron mutation that causes beta-thalassemia.
Our standard control oligo is a negative control Morpholino oligo that targets a human beta-globin intron mutation that causes beta-thalassemia.
These 25-base mixed oligos are synthesized with a random base mixture at every position. They are intended for use as a negative control. The concentration of any given sequence in this mixture should be well below the threshold of detectable biological activity.
This is a Morpholino oligo targeting zebrafish p53, reported to suppress apoptotic effects induced by some Morpholinos (Robu et al. 2007, PLoS Genetics).